Esomeprazole enteric coated capsule will be officially launched in late June

In late June, the national class 4 new drug esomeprazole enteric coated capsule independently developed by Laimei Pharmaceutical Co., Ltd will be officially launched, which means that the new drug research and development of esomeprazole, which started in 1999 and lasted for 15 years, has been successfully announced It is understood that the new drug is expected to become the largest single product sales revenue variety of Laimei pharmaceutical industry in the next few years, with an annual sales volume of 1 billion yuan, becoming the company's largest profit contributing variety With the sale of esomeprazole and ubilins, an immunomodulator to be launched in the second half of the year, the company's exclusive sales of new drugs will account for more than half Esomeprazole is a new generation proton pump inhibitor (PPI), which is mainly used in the treatment of peptic ulcer Compared with other proton pump inhibitors, esomeprazole has the advantages of shorter course of treatment, more stable effect, more rapid and lasting effect, and higher HP ulcer eradication rate It is the latest generation of drugs for the treatment of peptic ulcer According to the sales data of sample hospitals of Nanfang pharmaceutical Economic Research Institute, the sales scale of digestive system drugs exceeded 27 billion yuan in 2012, with a year-on-year growth of about 13% PPI drugs account for about 70% of the total, and esomeprazole, as a new generation of PPI drugs, is in a rapid growth period In 2013, esomeprazole accounted for 3.76% of the total sales of terminal digestive system drugs in sample hospitals of Nanfang Pharmaceutical Research Institute, with the fastest growth rate It is understood that at present, esomeprazole drugs sold in China are only imported from AstraZeneca, an international pharmaceutical giant, and there are no other manufacturers in China The success of self-developed Esomeprazole in Laimei pharmaceutical industry broke the monopoly of foreign pharmaceutical enterprises According to the current medical examination and approval system in China, lomesomeprazole enteric coated capsules have a monitoring and protection period of three years In the next three years, Lyme Pharma will have the exclusive right to produce and sell esomeprazole enteric coated capsules in China The reporter learned from Laimei pharmaceutical that since the beginning of this year, the company has carried out dealer investment promotion and target hospital coverage nationwide At present, the top three hospitals in China cover more than 60% of the total, and it is planned to reach 80% by the end of this year More than 20 major provinces have achieved dealer network coverage, and the new drug has been accepted into the local basic drug catalog in some provinces This year, the company will complete the largest in China Bidding and supplementary bidding in some provinces According to the approval of relevant regulatory authorities, the terminal retail price of laimeishu is temporarily determined to be 88 yuan per box, which is 4 yuan lower than the imported AstraZeneca products of the same specification, and the price gap is less than 5% Pharmaceutical professionals said that the price was set according to the new drug standard, and there was no need to refer to the pricing standard that the price of generic drugs was 15% to 30% lower than that of similar original research drugs Generally, the profit margin of imported drugs is large, while the terminal price of laimeishu is only less than 5% lower, and its gross profit margin level and profit margin are considerable According to the company's forecast, the sales volume of laimeishu in the second half of this year is expected to exceed 100 million yuan, and it is expected to achieve explosive growth next year The annual sales volume of laimeishu in about three years is expected to reach 1 billion yuan It is understood that compared with other new prescription drugs on the market, the imported esomeprazole preparation has been in China for several years, and it has good doctor and expert recognition and market basis, so the market promotion speed of lymesu will be faster The company expects that in the future, due to the stronger marketing channels of domestic drugs than imported drugs, the market share of esomeprazole will be at least half of that of laimeishu At present, the main battleground between laimeishu and imported drugs is in the top three hospital, while the involvement of imported drugs is less in the hospitals below the top three In the future, in addition to maintaining the market competition with imported drugs in the top three hospital, the company will also take the third Hospitals below grade A will be developed as key markets The reporter of China Securities News, the exclusive variety promotion of characteristic specialty, learned that in addition to esomeprazole, the exclusive variety Utilins introduced by Laimei pharmaceutical from Germany will also be officially listed in the second half of the year As a biological immunomodulator suitable for general medicine, Utilins has a large market space The company's annual production capacity of Utilins is 50 million pieces, and the annual sales revenue is expected to be more than 100 million yuan According to the 2013 annual report of Laimei pharmaceutical, the main revenue of pharmaceutical business is about 700 million yuan After the two major new drugs are listed, the annual sales will soon exceed 1 billion yuan and reach the scale of 2 billion yuan In recent years, Laimei pharmaceutical industry has been focusing on the development of specialty drugs with stronger competitiveness and higher entry threshold After the two 100 million yuan exclusive varieties of esomeprazole and Utilins are listed, the product structure and varieties of the company will also undergo subversive changes In terms of variety competitiveness, at present, the company's exclusive varieties account for less than 10%, while esomeprazole and utillin plus the existing lymphotracer (kanalin) and other varieties, the company's exclusive varieties will significantly increase the proportion of future revenue and exceed 50%; in terms of product structure, the current antibiotics and large infusion categories account for the largest proportion, more than 60%, while the future digestive, immune and anti swelling categories account for the largest proportion The proportion of tumors will be greatly increased to more than 50%, and the gross profit rate will be significantly improved, and the market competitiveness and profit level will be greatly improved.